Heberlig Chris 4
4 · Kiniksa Pharmaceuticals, Ltd. · Filed Mar 6, 2019
Insider Transaction Report
Form 4
Heberlig Chris
Exec VP & CFO10% Owner
Transactions
- Award
Share Option
2019-03-04+46,000→ 46,000 totalExercise: $17.92Exp: 2029-03-03→ Class A Common Shares (46,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.